Tyrosinase-related protein 2-specific T cell receptor-MHC class I complex (TRP2-TCR-MHC complex)

The Tyrosinase-related protein 2 (TRP2)-specific T cell receptor-MHC class I complex is a critical immunological assembly involved in the recognition of melanoma cells by the cellular immune system (UniProt: P40126). TRP2, also known as dopachrome tautomerase (DCT), is a melanocyte differentiation antigen that is highly expressed in both normal melanocytes and malignant melanoma cells (PubMed: 8691132). In this complex, a specific TRP2-derived peptide (e.g., SVYDFFVWL) is presented by Major Histocompatibility Complex (MHC) class I molecules, such as HLA-A*02:01, to the T cell receptor (TCR) of CD8+ cytotoxic T lymphocytes. This interaction is the fundamental basis for various immunotherapeutic strategies, including TCR-engineered T cell (TCR-T) therapy and peptide-based vaccines (PubMed: 30104634). By targeting this complex, therapies aim to direct the patient's immune system to selectively identify and destroy TRP2-expressing tumor cells. However, because TRP2 is also expressed in healthy melanocytes, a primary safety concern is the development of vitiligo or other autoimmune-related pigmentary changes (PubMed: 11015445). Clinical development focuses on optimizing TCR affinity to maximize anti-tumor efficacy while managing these off-tumor effects.

Other names

DCT-specific TCR-MHC complexDopachrome tautomerase-specific TCR-MHC complexTRP-2/HLA-A*02:01 complexTRP2-specific CD8+ T cell receptor

TCR-engineered T cells or vaccine-induced T cells recognize the TRP2 peptide presented by MHC class I molecules on the surface of melanoma cells, triggering the release of perforins and granzymes to induce apoptosis in the target tumor cells (PubMed: 21422470).